News for NAVB Stock

Navidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock Split Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax Assets Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024 Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024 Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications Navidea Biopharmaceuticals, Inc. Announces Intent to sell Cardinal Milestone Payment for $8 Million; Secures New $2.75 Million Equity Line of Credit Navidea Biopharmaceuticals, Inc. Enters Asset Purchase Agreement with Meilleur Technologies, Inc. for Rights to NAV4694 Navidea Biopharmaceuticals, Inc. Hires G2G Ventures as Executive Consultants; Chief Medical Officer Steps Down Navidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Company’s Cancer Immunotherapy Pipeline Navidea Biopharmaceuticals Files Appeal in CRG Case Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual Meeting Navidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant Radiopharma Navidea Biopharmaceuticals Announces Oral Ruling in Case Involving Attorney’s Fees Navidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business Update Navidea Biopharmaceuticals Announces Subscriptions of Approximately $14.2 Million from its Rights Offering Navidea Biopharmaceuticals Announces Extension of Subscription Period to August 24, 2022 and Updated Terms of its Previously Announced Rights Offering Navidea Biopharmaceuticals Reports Second Quarter 2022 Financial Results Navidea Biopharmaceuticals Announces Commencement of Rights Offering Subscription Period and Updated Terms of its Previously Announced Rights Offering Navidea Biopharmaceuticals Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia Navidea Biopharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record for the Previously Announced Rights Offering Navidea Biopharmaceuticals Announces Publication of Study Examining Tc99m Tilmanocept Imaging of Arterial Inflammation in People with HIV Navidea Biopharmaceuticals Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering Navidea Biopharmaceuticals Announces Additional Bridge Loan Funding Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Tumor Myeloid-Directed Therapies Summit Annual Meeting Navidea Biopharmaceuticals Reports First Quarter 2022 Financial Results Navidea Biopharmaceuticals to Host First Quarter 2022 Earnings Conference Call and Business Update Navidea Biopharmaceuticals Announces Positive Preliminary Results of Its Ongoing Phase 2B Study Comparing Tc99m Tilmanocept Imaging with Histopathology of Joints from Patients with Rheumatoid Arthritis Navidea Biopharmaceuticals Announces Updated Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis for U.S. and EU Markets Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Diagnosis and Treatment of Leishmaniasis Navidea Biopharmaceuticals Announces the Regulatory Approval of Lymphoaim in India Navidea Biopharmaceuticals Announces Adoption of Plan Designed to Protect NOLs and Other Tax Assets, Closing of Bridge Loan Financing, and Business Update Q&A Series Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American Navidea Biopharmaceuticals Announces New Senior Regulatory Consultant and Return of Former Director of Regulatory Affairs CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results Navidea Biopharmaceuticals to Host Fourth Quarter 2021 Earnings Conference Call and Business Update Navidea Biopharmaceuticals Announces Research Agreement with the University of Pennsylvania Evaluating Tc99m Tilmanocept as a Prognostic Marker for Glioblastoma Navidea Biopharmaceuticals Announces Settlement of Platinum Litigation; Receipt of Noncompliance Notice from NYSE American Navidea Biopharmaceuticals Announces Launch of Phase 3 Clinical Trial in Rheumatoid Arthritis Navidea Biopharmaceuticals Completes Full Enrollment in Phase 2b Normative Database Study to Support its Rheumatoid Arthritis Program Navidea Biopharmaceuticals Terminates Stock Purchase Agreement Navidea Biopharmaceuticals Announces Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis Navidea Biopharmaceuticals Announces Business Update Call and Changes to Board of Directors Composition Navidea Biopharmaceuticals Reports Third Quarter 2021 Financial Results Navidea Biopharmaceuticals to Host Third Quarter 2021 Earnings Conference Call and Business Update Navidea Biopharmaceuticals Announces Resignation of Jed A. Latkin Navidea Biopharmaceuticals Appoints Michel Mikhail, Ph.D. as Chief Regulatory Officer Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition Navidea Biopharmaceuticals Reports Second Quarter 2021 Financial Results Navidea Biopharmaceuticals to Host Second Quarter 2021 Earnings Conference Call and Business Update Navidea Biopharmaceuticals Announces First 110 Subjects Imaged in NAV3-35 Normative Database Phase 2b Study to Support Rheumatoid Arthritis Indications Navidea Biopharmaceuticals Announces End-of-Phase 2 Type B Meeting Request Granted by the FDA to Discuss Ongoing Clinical Program in Rheumatoid Arthritis Macrophage Therapeutics, Inc. Wins Delaware Case Against Michael Goldberg for Breach of Fiduciary Duty Navidea Biopharmaceuticals Announces Issuance of U.S. Patent for Diagnosis and Treatment of Viral Infections Navidea Biopharmaceuticals Reports First Quarter 2021 Financial Results Navidea Biopharmaceuticals Announces NIH Grant Award to UC San Diego for Clinical Study Evaluating Tc99m Tilmanocept as a Kidney Imaging Agent Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition Navidea Biopharmaceuticals to Host First Quarter 2021 Earnings Conference Call and Corporate Update Navidea Biopharmaceuticals Announces Acceptance of Therapeutics Focused Abstract for Presentation at the Frontiers in Cancer Immunotherapy Symposium Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results Navidea Biopharmaceuticals to Host Fourth Quarter 2020 Earnings Conference Call and Corporate Update Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference Navidea Biopharmaceuticals Announces $5 Million Private Placement with Existing Investor Navidea Biopharmaceuticals Announces Submission of Formal Type B Meeting Request with FDA and Launch of NAV3-32 Phase 2B Trial in Rheumatoid Arthritis Navidea Biopharmaceuticals to Present at the 2021 ICR Conference On January 14, 2021 Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter Navidea Biopharmaceuticals Announces Full Enrollment in its Ongoing Phase 2B Trial of Tc99m Tilmanocept in Rheumatoid Arthritis (RA)